The last two decades have been an exciting era for GBM researchers, heralded by the adoption of TMZ into standard-of-care and the emergence of novel therapeutic agents such as PARP, ATM and ATR inhibitors, with promising early data. This evidence concerns the gene ATR and glioblastoma.